Corbus Pharmaceuticals (NASDAQ:CRBP)‘s stock had its “buy” rating reissued by Noble Financial in a report issued on Tuesday.
A number of other equities research analysts have also weighed in on CRBP. Cantor Fitzgerald set a $28.00 price objective on Corbus Pharmaceuticals and gave the company an “overweight” rating in a research note on Thursday, December 14th. BidaskClub lowered Corbus Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Wednesday, December 20th. Raymond James Financial started coverage on Corbus Pharmaceuticals in a research note on Friday, January 19th. They set an “outperform” rating and a $24.00 price objective for the company. Finally, ValuEngine upgraded Corbus Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Thursday, March 1st. Two research analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. The stock presently has a consensus rating of “Buy” and a consensus price target of $25.75.
Shares of Corbus Pharmaceuticals (NASDAQ CRBP) traded up $0.05 during midday trading on Tuesday, reaching $6.80. The company’s stock had a trading volume of 919,941 shares, compared to its average volume of 1,000,000. Corbus Pharmaceuticals has a 12-month low of $5.30 and a 12-month high of $10.50. The firm has a market cap of $378.10, a price-to-earnings ratio of -10.63 and a beta of 152.04.
Large investors have recently added to or reduced their stakes in the business. State Board of Administration of Florida Retirement System bought a new position in Corbus Pharmaceuticals during the 3rd quarter worth approximately $108,000. Yellowstone Partners LLC bought a new position in Corbus Pharmaceuticals during the 3rd quarter worth approximately $110,000. Voya Investment Management LLC bought a new position in Corbus Pharmaceuticals during the 2nd quarter worth approximately $125,000. Aries Wealth Management bought a new position in Corbus Pharmaceuticals during the 4th quarter worth approximately $153,000. Finally, Nationwide Fund Advisors bought a new position in Corbus Pharmaceuticals during the 2nd quarter worth approximately $158,000. 38.03% of the stock is currently owned by institutional investors.
TRADEMARK VIOLATION WARNING: “Noble Financial Reaffirms “Buy” Rating for Corbus Pharmaceuticals (CRBP)” was posted by American Banking News and is the sole property of of American Banking News. If you are reading this piece of content on another site, it was stolen and reposted in violation of United States and international copyright & trademark law. The original version of this piece of content can be accessed at https://www.americanbankingnews.com/2018/03/14/noble-financial-reaffirms-buy-rating-for-corbus-pharmaceuticals-crbp.html.
Corbus Pharmaceuticals Company Profile
Corbus Pharmaceuticals Holdings, Inc is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of therapeutics to treat rare, chronic and serious inflammatory and fibrotic diseases. The Company operates through developing and commercializing therapeutics to treat rare life-threatening inflammatory fibrotic diseases segment.
Receive News & Ratings for Corbus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corbus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.